SRSreeja Biswas Roy

Sreeja Biswas Roy

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Sreeja Biswas Roy has a total of 84 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Lung hernia: an updated narrative review

    by Vladislav Muldiiarov, Mark Shacker, Sreeja Biswas Roy, Rajat Walia, Samad Hashimi, Michael A. Smith, Lara Schaheen, Ross M. Bremner, Ashwini Arjuna

    Background and Objective: Pulmonary (lung) hernia is an uncommon condition in which aerated lung protrudes beyond the normal confines of the thorax through a defect at the thoracic inlet, chest wall, mediastinum, or diaphragm. Although historically linked to trauma, recent reports increasingly involve postoperative patients, including those after lung transplantation, and situations associated with repeated spikes in intrathoracic pressure. We conducted a narrative review to summarize contemporary diagnosis and management. Methods: We performed a targeted literature search of MEDLINE (via PubMed), ScienceDirect, the Cochrane Library, Taylor and Francis Online, and ClinicalTrials.gov from inception through December 31, 2025. The search was performed in January 2026. We included studies in English or French describing pulmonary or lung hernia of any anatomic subtype or etiology in humans. We extracted data on hernia location, suspected cause, clinical presentation, imaging, management strategy, complications, and outcomes. Key Content and Findings: The literature is dominated by case reports and small series with heterogeneous definitions and inconsistent reporting of defect anatomy, operative technique, and follow-up. Most published cases involve thoracic or intercostal defects, while cervical hernias are less common and mediastinal or diaphragmatic variants are rare. Computed tomography is the primary diagnostic test, sometimes supported by dynamic maneuvers to reproduce the protrusion. Management is guided by symptoms and anatomy. Observation is often chosen for small, reducible defects, whereas progressive enlargement, pain, impaired reducibility, concern for incarceration, ventilatory dependence, or chest wall instability typically lead to operative repair with reconstruction and selective reinforcement. Conclusions: More consistent reporting and multicenter data are needed to define progression risk and compare surgical techniques and materials, particularly in high-risk postoperative and post-thoracic transplant populations.

  • Impact of recipient–donor risk matching on graft survival after lung transplantation

    by Michael T. Olson, Ashwini Arjuna, Mark Shacker, Rajat Walia, Lara Schaheen, A. Samad Hashimi, Ross M. Bremner, Michael A. Smith, Sreeja Biswas Roy


  • Open Access

    Balancing cancer recurrence risk and respiratory mortality: Immediate listing for lung transplantation following HCC therapy

    by Fadi Zaiem, Vladislav Muldiiarov, Sreeja Biswas Roy, Rajat Walia, Ashwini Arjuna


  • Bridging the Gap: A Comparative Analysis of Patients Requiring Mechanical Ventilation or ECMO as a Bridge to Lung Transplant Between Eras

    by Sreeja Biswas Roy, Ariba Moin, Artur Rybachok, Mark Shacker, Ashwini Arjuna, Rajat Walia, Samad Hashimi, Jasmine Huang, Michael A. Smith, Ross M. Bremner

    BACKGROUND: We compared trends and outcomes of lung transplant recipients who were bridged to transplantation using mechanical ventilation (MV) or extracorporeal membrane oxygenation (ECMO) during the new Composite Allocation Score (CAS) era or the previous Lung Allocation Score (LAS) era. METHODS: The United Network for Organ Sharing database was queried for all adult lung transplant recipients bridged to transplant with MV or ECMO during the LAS (April 5, 2005 to August 3, 2023) or CAS (September 3, 2023 to September 30, 2024) era. Baseline patient characteristics, perioperative outcomes, and short‐term survival were compared between eras. RESULTS: A total of 2982 patients were included: 1866 with ECMO‐bridge (LAS‐ECMO: 1597; CAS‐ECMO: 269) and 1116 with MV‐bridge (LAS‐MV: 1072; CAS‐MV: 44). MV‐bridge use was higher during LAS than CAS (LAS, 2.9% vs. CAS, 0.8%, p < 0.001), whereas ECMO‐bridge was higher in the CAS era (LAS, 4.3% vs. CAS, 5.3%, p = 0.03). Recipient age was higher for both MV‐bridge and ECMO‐bridge cohorts in the CAS era. Median waitlist times were shorter, and median ischemic time and donor organ travel distances were longer in the CAS era for both MV and ECMO cohorts. Perioperative outcomes and 30‐day and 90‐day survival were comparable between eras. Waitlist mortality and delisting rates for medical deterioration were lower in the CAS era. CONCLUSIONS: Rates of ECMO‐bridge to transplant increased in the CAS era compared to the LAS era. Although the donor lung travel distances were longer, perioperative outcomes were comparable to those of the LAS era. Long‐term outcomes of BTT candidates in the CAS era remain to be seen.


  • Open Access

    A Rare Case of Orthostasis, Dizziness, and Non-O1, Non-O139 Vibrio cholerae Infection in a Lung Transplant Recipient

    by Michael T. Olson, Tejus Walia, Satish Chandrashekaran, Sreeja Biswas Roy, Ashwini Arjuna

    Non-O1, non-O139 Vibrio cholerae are rare strains that are generally nonpathogenic in immunocompetent hosts. However, this pathogen has been shown to cause gastroenteritis, wound infections, or bacteremia in immunocompromised patients and is associated with significant mortality in these hosts. Herein, we describe a case of hemorrhagic enterocolitis in a lung transplant recipient with an atypical presentation of non-O1, non-O139 V. cholerae and ongoing orthostasis. The patient reported recent seafood consumption and was managed appropriately with antibiotic therapy before necessitating esophagogastroduodenoscopy (EGD) for further objective testing.


  • Management and Outcomes of Diverticulitis After Lung Transplantation

    by Michael T. Olson, Shaimaa Elnahas, Jonathan Dameworth, David Row, Ronald A. Gagliano, Sreeja Biswas Roy, Paul Kang, Rajat Walia, Ross M. Bremner

    Most lung transplant patients are older than 50 years. Complications from colonic diverticula are not uncommon, especially with chronic immunosuppression. However, limited data exist regarding the optimal management of these patients. We sought to investigate the incidence, risk factors, and outcomes of diverticulitis after lung transplant. We conducted a retrospective study to review patients undergoing lung transplant between 2007 and 2016 with posttransplant acute colonic diverticulitis. Patients were grouped based on medical or surgical management. Of 512 transplant recipients, 17 (3.32%) developed 26 episodes of diverticulitis over a median follow-up of 39 months. Nine patients had documented diverticulosis on pretransplant colonoscopy. These patients had a higher incidence of surgical intervention for diverticulitis, were more likely to have recurrent diverticulitis, and had longer lengths of stay than patients without pretransplant diverticulosis. Six (35.3%) of 17 patients required surgery (ie, Hartmann procedure; 4 during the initial episode and 2 during their third and fourth episodes); 11 patients (64.7%) were managed with antibiotics alone. Patients in the surgical group presented earlier posttransplant (P = .004) and were on higher doses of tacrolimus (P = .03). Six (46.1%) of 13 patients with medically managed first episodes of diverticulitis experienced recurrence. No recurrence occurred after surgical management. No deaths were attributable to diverticulitis in either group. Patients with pretransplant diverticulosis experienced earlier, more complicated episodes of diverticulitis posttransplant than patients without. Surgical patients received higher doses of tacrolimus and presented earlier than medical patients. Uncomplicated diverticulitis in posttransplant patients can be managed medically, even in the case of recurrent, uncomplicated disease.


  • Open Access

    Unique IL-13Rα2/STAT3 mediated IL-13 regulation detected in lung conventional dendritic cells, 24 h post viral vector vaccination

    by Sreeja Roy, Ho-Ying Liu, Muhammad Irwan Jaeson, Lachlan Paul Deimel, Charani Ranasinghe

    This study demonstrates that 24 h following viral vector-based vaccination IL-13Rα2 functions as a master sensor on conventional dendritic cells (cDCs), abetted by high protein stability coupled with minimal mRNA expression, to rapidly regulate DC mediated IL-13 responses at the lung mucosae, unlike IL-13Rα1. Under low IL-13, IL-13Rα2 performs as a primary signalling receptor, whilst under high IL-13, acts to sequester IL-13 to maintain homeostasis, both in a STAT3-dependent manner. Likewise, we show that viral vector-derived IL-13 levels at the vaccination site can induce differential STAT3/STAT6 paradigms in lung cDC, that can get regulated collaboratively or independently by TGF-β1 and IFN-γ. Specifically, low IL-13 responses associated with recombinant Fowlpox virus (rFPV) is regulated by early IL-13Rα2, correlated with STAT3/TGF-β1 expression. Whilst, high IL-13 responses, associated with recombinant Modified Vaccinia Ankara (rMVA) is regulated in an IL-13Rα1/STAT6 dependent manner associated with IFN-γR expression bias. Different viral vaccine vectors have previously been shown to induce unique adaptive immune outcomes. Taken together current observations suggest that IL-13Rα2-driven STAT3/STAT6 equilibrium at the cDC level may play an important role in governing the efficacy of vector-based vaccines. These new insights have high potential to be exploited to improve recombinant viral vector-based vaccine design, according to the pathogen of interest and/or therapies against IL-13 associated disease conditions.


  • Prevalence and Natural History of Barrett’s Esophagus in Lung Transplant: A Single-Center Experience

    by Sreeja Biswas Roy, Paul Banks, Matthew Kunz, Taylor R. Ipsen, Takahiro Masuda, Sumeet K. Mittal, Michael A. Smith, Ross M. Bremner


  • Development of Squamous Cell Carcinoma After Pulmonary Aspergillosis in the Native Lung of a Lung Transplant Recipient: A Case Report

    by N. Madan, H. Abdelrazek, P.D. Patil, M. D. Ross, S.B. Roy, N. Thawani, M.F. Hahn, R.M. Bremner, T.S. Panchabhai


  • Electromagnetic navigational bronchoscopy for diagnosing peripheral lung lesions in lung transplant recipients: a single-center experience

    by Tanmay S. Panchabhai, Sreeja Biswas Roy, Nikhil Madan, Hesham Abdelrazek, Vipul J. Patel, Rajat Walia, Ross M. Bremner

    Electromagnetic navigational bronchoscopy for diagnosing peripheral lung lesions in lung transplant recipients: a singlecenter experience